

Auswahl an Publikationen
von Prof. Schmidt-Wolf zum Schwerpunkt Nierenzellkarzinom:

1. Schmidt-Wolf IGH, Neubauer A, Finke S, Csipai M, Wittig B, Huhn D. Interleukin-7 gene therapy for patients with metastatic colon cancer, renal cell cancer, malignant melanoma or lymphoma. *Human Gene Ther* 5(9), 1161-1168 and 1197 (1994)
2. Schmidt-Wolf IGH, Finke S, Trojaneck B, Denkena A, Lefterova P, Schwella N, Heuft HG, Prange G, Korte M, Takeya M, Dorbic T, Neubauer A, Wittig B, Huhn D. Phase I clinical study applying autologous immunologic effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. *Brit J Cancer* 81(6):1009-1016 (1999)
3. Trojaneck B, Niemitz S, Micka B, Lefterova P, Schmidt-Wolf IGH. Establishment and characterization of colon carcinoma and renal cell carcinoma primary cultures. *Cancer Biother & Radiopharm* 15(2):169-174 (2000)
4. Märten A, Flieger D, Renoth S, Weineck S, Albers P, Compes M, Schöttker B, Ziske C, Engelhart S, Hanfland P, Krizek L, Faber C, von Rücker A, Müller S, Sauerbruch T, Schmidt-Wolf IGH. Therapeutic vaccination against metastatic renal cell carcinoma by autologous dendritic cells: Preclinical results and outcome of a first clinical phase I/II trial. *Cancer Immunol Immunother* 51:637-644 (2002)
5. Märten A, Renoth S, Heinicke T, Albers P, Pauli A, von Lilienfeld-Toal M, Caspari R, Flieger D, Hanfland P, von Rücker A, Eis-Hübinger AM, Müller S, Schwaner I, Lohmann U, Heylmann G, Sauerbruch T, Schmidt-Wolf IGH. Allogeneic dendritic cells fused with tumor cells: Preclinical results and outcome of a first clinical phase I/II trial in patients with renal cell carcinoma. *Hum Gene Ther* 4(5):483-494 (2003)
6. Sievers E, Albers P, Schmidt-Wolf IGH, Märten A. Telomerase pulsed dendritic cells for immunotherapy of renal cell carcinoma. *J Urology* 171:114-119 (2004)
7. Märten A, Sievers E, Albers P, Müller S, Franchy C, von Ruecker A, Strunk H, Schild HH, Schmiedel A, Sommer T, Sauerbruch T, Schmidt-Wolf IGH. Telomerase-pulsed dendritic cells: Preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma. *German Medical Science* 4: Doc02 (2006)
8. Sievers E, Haferkamp A, Dreimüller P, Schmidt-Wolf IGH, Schmidt J, Märten A. Characterization of primary renal carcinoma cultures. *Urologia Internationalis*, in Druck
9. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, Mc Dermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IGH, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer R. Temsirolimus, Interferon alfa, or both for Advanced Renal-Cell Carcinoma. *NEJM (The New England Journal of Medicine)* 356(22):2271-2281 (2007)
10. Kraemer A, Hauser S, Kim Y, Gorschlüter M, Müller SC, Brossart P, Schmidt-Wolf I. Phase I trial of metastatic renal cell carcinoma. with oral capecitabine and thalidomide. *GMS Vol* 7, 2009 (online)

11. Kraemer M, Hauser S, Schmidt-Wolf I. Long-term survival of patients with metastatic renal cell carcinoma treated with pulsed dendritic cells. *Anticancer Res.* 2010 Jun;30(6):2081-
12. Jäkel C, Hauser S, Rogenhofer S, Müller SC, Brossart P, Schmidt-Wolf IGH. Clinical studies applying cytokine-induced killer cells for the treatment of renal cell carcinoma. *Clinical and Developmental Immunology* vol. 2012, Article ID 473245, 7 pages, 2012. doi:10.1155/2012/473245. IF: 3,4
13. Koller CM, Kim Y, Schmidt-Wolf IGH. Targeting renal cancer with a combination of WNT inhibitors and a bi-functional peptide. *Anticancer Res.* 2013 Jun;33(6):2435-40. IF 1,7